News tagged with erlotinib
'Happy hour' gene discovery suggests cancer drugs might treat alcoholism
A class of drugs already approved as cancer treatments might also help to beat alcohol addiction. That's the conclusion of a discovery in flies of a gene, dubbed happyhour, that has an important and previously unknown role ...
May 21, 2009 |
4.8 / 5 (4) |
1
Patient access schemes for high-cost cancer medicines: Good in theory, difficult in practice
created by the pharmaceutical industry to allow access to expensive cancer drugs—can be fraught with administrative problems, meaning that money does not reach the parts of the UK National Health Service that it should, ...
Jan 31, 2010 |
5 / 5 (1) |
0
Afatinib benefits lung cancer patients whose cancer progressed after treatment with EGFR inhibitors
Lung cancer patients who have already been treated with the EGFR inhibitors erlotinib or gefitinib seem to gain further benefits in terms of progression-free survival and tumor shrinkage when treated with the new drug afatinib, ...
Oct 12, 2010 |
5 / 5 (1) |
1
Personalized medicine: Tumor analysis reveals new opportunities for existing cancer drugs
Targeted cancer therapies such as trastuzumab (Herceptin), gefitinib (Iressa) and erlotinib (Tarceva) could be used to treat a wider range of cancers than previously thought, according to new research presented today (Wednesday) ...
Nov 17, 2010 |
5 / 5 (1) |
0
Oncogene AEG-1 strongly predicts response to erlotinib treatment in EGFR-mutant lung cancer
Spanish researchers have identified a gene whose expression level strongly predicts how well certain lung cancer patients will respond to treatment with the drug erlotinib.
Feb 25, 2011 |
5 / 5 (1) |
0
Erlotinib
Erlotinib hydrochloride (trade name Tarceva) is a drug used to treat non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is a reversible tyrosine kinase inhibitor, which acts on the epidermal growth factor receptor (EGFR). It is marketed in the United States by Genentech and OSI Pharmaceuticals and elsewhere by Roche. In lung cancer, it extends life by an average of 3.3 months at a cost of CDN$95,000.
For more information about Erlotinib, read the full article at
Wikipedia.
This text uses material from Wikipedia and is available under the GNU Free Documentation License.
